Real-world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus

Diabetes Obes Metab. 2024 Apr 10. doi: 10.1111/dom.15590. Online ahead of print.

Authors

Lixin Guo¹, Yue Xi², Li Li³, Kunquan Guo⁴, Jun Wu⁵, Jiawei Xu⁶, Yihua Wang⁶, Guangyu Wu⁶, Si Si⁶

Affiliations

¹ Beijing Hospital, Beijing, China.
² The Third Affiliated Hospital of Jinzhou Medical University, Liaoning, China.
³ The First Affiliated Hospital of Ningbo University, Zhejiang, China.
⁴ Shiyan General Hospital of Dongfeng Motor, Hubei, China.
⁵ The Third Hospital of Wuhan, Hubei, China.
⁶ Eli Lilly and Company, Suzhou, China.

PMID: 38600796
DOI: 10.1111/dom.15590

No abstract available

Keywords: GLP‐1 receptor agonists; diabetes treatment satisfaction questionnaire; dulaglutide; treatment satisfaction; type 2 diabetes mellitus.

Publication types

Letter

Grants and funding

Eli Lilly and Company